Wuhan Desheng Biochemical Technology Co., Ltd

In discussions on cell culture, HEPES is often described as "low toxicity". This statement is correct in direction, but it can easily be misinterpreted as "no upper limit" - in actual work, if the three things of concentration, light, and osmotic pressure are not handled properly, the experimental results will still deviate. 1.Widely cited safety intervals The general recommendation given by Desheng is 10-25 mM, which can be used to supplement buffering capacity when operating outside the incubator. The common formulas for commercially available culture media also fall within this range: for example, DMEM/F-12 often contains 15mM, and DMEM often contains 25mM. The reason why this interval is repeatedly quoted is that it satisfies two conditions simultaneously: the buffer capacity is sufficient to cope with pH fluctuations in conventional operations, while the additional osmotic pressure introduced is still within the acceptable range of the cell. 2.Where does the upper limit of concentration come from There are three main reasons why the concentration cannot be infinitely increased. 1. Osmotic pressure. This is the most direct one. Adding HEPES in the form of free acid, alkali, or sodium salt will increase the osmotic pressure of the solution. The tolerance range of most mammalian cells is between 260-350mOsm/kg. The higher the concentration, the more amount needs to be deducted from NaCl or NaHCO3, and the less room for adjusting the formula. 2. Phototoxicity. This is an easily overlooked point. HEPES can generate reactive oxygen species such as hydrogen peroxide under visible light irradiation, especially in the presence of riboflavin in the culture medium. Therefore, the culture medium containing HEPES needs to be stored and handled away from light; For experiments with long-term light imaging, it is suggested to use MOPS system or adopt methods such as reducing light intensity and adding reactive oxygen species scavengers. 3. Direct effects of high concentration. Technical data suggests that when the concentration exceeds 40 mM, some cell lines may experience inhibited proliferation and morphological changes. It should be clarified that there are significant cell line differences in the sensitivity of such effects, and not all cells are the same, nor is there a universal "toxicity threshold". 3.Why does the conclusion of 'toxicity' always seem vague When consulting relevant materials, it can be found that the conclusions about the cytotoxicity of HEPES are often inconsistent. This is not a matter of data quality, but rather a significant difference in the experimental conditions themselves: Different cell types: The tolerance of tumor cell lines to primary cells and stem cells can differ significantly Different lighting conditions: exposure time and light intensity directly affect the generation of reactive oxygen species Different components of the culture medium: the content of photosensitive components such as riboflavin is a key variable Different exposure durations: short-term operations of a few hours versus long-term cultivation of several days, conclusions cannot be directly compared Different endpoints are determined: proliferation inhibition, morphological changes, apoptosis, metabolic activity, measuring different things Therefore, when seeing the conclusion that "a certain concentration is toxic to a certain cell", one should first confirm whether its experimental conditions are comparable to their own system. 4.Determine the working concentration for one's own cells Instead of using other people's numbers, a more reliable approach is to conduct a small-scale gradient experiment: Set gradients: 0, 10, 15, 20, 25mM (if you want to explore the upper limit, you can add a 40mM group) Unified pH: Adjust the final pH of all groups to be consistent (such as 7.4) to avoid misjudging pH differences as concentration effects Simultaneous inoculation: Cell density, basic formula of culture medium, and serum batch remain consistent, with 0mM as the control Observation period: Covering your actual cultivation period, such as 5-7 days Monitoring indicators: Daily microscopic observation of morphology and convergence, endpoint quantified by vitality testing (such as CCK-8, MTT, or table blue) Record osmotic pressure: Record the measured osmotic pressure of each group together to distinguish between concentration effect and osmotic pressure effect For sensitive cells such as primary cells and stem cells, it is recommended to start testing at lower concentrations and record the lighting conditions together. 5.Four operational habits to reduce risks The concentration should not exceed 25mM unless there is clear experimental evidence to support higher concentrations The entire process is protected from light, and both the reserve solution and culture medium are stored away from light Recheck the osmotic pressure and measure it once every time the formula is adjusted Selecting cell culture grade raw materials with stricter control over indicators such as endotoxins and heavy metals, resulting in less interference with sensitive cells HEPES' 'low toxicity' is a relative concept, not an unlimited passport. By simultaneously controlling concentration, osmotic pressure, and light exposure, and conducting a gradient validation on one's own cells, most questions about toxicity can be answered clearly. Hubei Xindesheng Material Technology Co., Ltd. provides customized supply methods from conventional models to indicators in the field of biological buffering agents. Customers can propose indicators such as purity, metal ion residue, and UV absorption based on their own experimental systems. The company is headquartered in Guanggu United Science and Technology City, Gedian Development Zone, Ezhou, Hubei Province, with two bases in Gedian and Huanggang. The annual production capacity of all categories is 5000 tons.

1.Why choose Tris when there are so many pH regulators? In the design of industrial ink formulations, the selection of pH regulators may seem simple, but it actually involves balancing multiple technical parameters such as buffering capacity, surface activity, compatibility, and long-term stability. Common pH regulators include ammonia water, triethanolamine (TEA), sodium hydroxide, various Good's buffers, etc. So, what makes Tris buffer stand out as the preferred choice for high-end ink formulations such as inkjet ink and digital printing ink? 2.Tris's molecular structure code: one molecule, two functions The molecular formula of Tris (trihydroxymethylaminomethane) is C ₄ H ₁₁ NO ∝, with a central carbon atom as the core, connecting three hydroxymethyl groups (- CH ₂ OH) and one primary amino group (- NH ₂). This structure endows Tris with a unique dual function: Primary amino (- NH ₂): Provides alkalinity and pH buffering ability, pKa=8.06 (25 ℃), effective buffering range pH 7.0-9.0 Three hydroxymethyl groups (- CH ₂ OH): endow molecules with polarity and surface activity, enabling them to possess both wetting and dispersing functions One molecule plays both the role of pH regulator and surfactant - this is the core reason why Tris is difficult to replace in ink formulations. 3.The Four Major Technical Functions of Tris in Ink 3.1 pH buffering: ensuring long-term stability of ink The pH value of ink directly affects the solubility stability of dyes, the dispersion state of pigments, and the service life of print heads. The effective buffering range of Tris is pH 7.0-9.0-4, which precisely covers the suitable pH range for most industrial inks (usually 6-10). More importantly, the Tris buffer system can continuously maintain pH stability during long-term ink storage - something that volatile bases such as ammonia cannot achieve (ammonia volatilization can cause a continuous decrease in pH). 3.2 Pigment dispersion control: ensuring dispersion effect from the source The synthesis (coupling reaction) stage of pigments is crucial in the production of pigment based inks. Research has shown that when using simple ammonia instead of Tris, appropriate dispersion effects cannot be achieved. The mechanism lies in: The pH will change rapidly during the coupling reaction process Tris, as a pH buffer under alkaline conditions, can inhibit pH mutations Thereby controlling the uniform growth of pigment particles Provide favorable conditions for the adsorption of dispersant polymers on the surface of pigment particles In contrast, Good's buffer with buffering effect in more acidic regions is difficult to achieve appropriate dispersion effect. 3.3 Surface Activity: Improving Wetting and Penetration The three hydroxymethyl groups in Tris molecule give it a certain surface activity. In ink formulations, Tris can: Reduce the surface tension of ink and improve its wettability to printing media Promote the uniform spreading of ink on different media surfaces such as paper, fabric, plastic, etc Improve the clarity and color saturation of printed materials 3.4 Metal ion compatibility: does not interfere with the reaction system Tris does not chelate with common metal ions such as Ca ² ⁺ and Mg ² ⁺, and does not deprive the ink formulation of any metal cofactors that may be required. At the same time, Tris itself does not introduce metal ions such as sodium and potassium, avoiding the problem of metal ion contamination that traditional inorganic bases may cause. 4.Tris vs other pH regulators: Technical parameter comparison Comparison Dimension Tris ammonia water Triethanolamine Sodium hydroxide Buffer Capacity ★★★★★ ★ ★★★ ★ Extremely Low without tall low Nothing surface activity have Nothing have Nothing Introduction of metal ions Nothing Nothing Nothing introduction of Na ⁺ Long term pH stability Excellent Poor good general Recommended addition amount 0.1%-2%- — — —   5.Process suggestions 5.1 Recommended addition amount of Tris According to patent literature, the content of Tris in ink compositions is usually 0.1% to 2% (by mass), preferably 0.3% to 1.5%. The specific amount of addition needs to be determined through experiments based on the initial pH, target pH, and buffering capacity requirements of the ink system. 5.2 Process precautions Dissolving sequence: It is recommended to add Tris in the early stage of ingredient preparation to ensure sufficient dissolution before adding other components PH adjustment: Tris itself is weakly alkaline. If further pH adjustment is needed, it can be used in conjunction with Tris HCl buffer system- Dark storage: Tris buffer is prone to absorbing carbonase-4 from the air, and should be sealed and stored in the dark after preparation Temperature effect: The pKa of Tris varies with temperature (Δ pKa/℃ ≈ -0.031), and pH shift should be noted in high temperature environments Hubei Xindesheng Material Technology Co., Ltd. has been specializing in the research and production of Tris for more than ten years. The product purity is stable at over 99%, with batch differences ≤ 1%, which can meet the consistency and reliability requirements of industrial ink formulations for Tris raw materials. The company has an independent R&D team that can assist customers in formula adaptation and process optimization. We welcome R&D departments of various ink companies to call or write to discuss technical issues.

Industry background: The biological buffer market is entering a period of rapid growth In recent years, with the continuous expansion of the global biopharmaceutical industry, the continuous iteration of in vitro diagnostic (IVD) technology, and the increasing investment in life science research, the market demand for biological buffering agents, as the core chemical raw materials for maintaining pH stability in biological systems, is experiencing unprecedented rapid growth. According to statistics, the market size of China's biological buffer industry has reached 2.357 billion yuan by 2025, a year-on-year increase of 7.97%. With the popularization of molecular diagnosis and immune detection technologies, the demand for high-end biological buffering agents such as HEPES, MOPS, TRIS continues to rise. The rapid development of cutting-edge fields such as cell and gene therapy (CGT) has also opened up new growth opportunities for the biological buffer market. From a global perspective, the bio buffer market also maintains strong growth momentum. According to Marketresearch.biz report, the global market size of biological buffering agents is expected to grow from $754 million in 2022 to $1.859 billion in 2032. Another organization predicts that the global market size of biological buffering agents will exceed 1.09 billion US dollars by 2026, and is expected to exceed 2.18 billion US dollars by 2035. In terms of segmented products, taking New Desheng's core product Tris as an example, the global Tris market is expected to grow from $770 million in 2025 to $950 million in 2026, and expand to $6.89 billion by 2035, with a compound annual growth rate of 24.65% from 2026 to 2035. The use of Tris as a buffering agent in drug formulation, bioprocessing, and molecular biology research continues to increase, and the demand for high-purity products is particularly strong. Another core product, HEPES, also saw significant growth. According to QYResearch, the global HEPES market sales have reached 531 million yuan by 2025, and are expected to climb to 952 million yuan by 2032, with a compound annual growth rate of 8.8%. HEPES is widely used in fields such as cell culture and IVD reagents, and the market demand continues to release. Domestic substitution accelerates, upstream raw material enterprises usher in strategic opportunities It is worth noting that against the backdrop of increasing global geopolitical risks and growing emphasis on supply chain security, the domestic substitution process for biological buffering agents is accelerating comprehensively. As the starting year of the 15th Five Year Plan, 2026 is accelerating the formation of a clear policy system to support domestic scientific research reagents. Beijing, Shanghai, Suzhou, Shenzhen and other places have explicitly included "domestication of biological reagents" in their local biopharmaceutical industry special plans. The 14th Five Year Plan for the Development of Bioeconomy lists buffer solutions as key consumables for research and development, and the country continues to increase support for upstream core raw materials in biomedicine. Under the dual demands of supply chain security and cost reduction and efficiency improvement, domestic biopharmaceutical and IVD enterprises are accelerating the introduction of high-quality local suppliers. The core raw materials upstream of the in vitro diagnostic industry chain, including diagnostic enzymes, antigens/antibodies, biological buffering agents, chemical raw materials, etc., are accelerating the breakthrough of import dependence. New Desheng: Deeply cultivating IVD core raw materials and embracing market opportunities with a full range of product layouts Since its establishment, Hubei Xindesheng Material Technology Co., Ltd. has always focused on the field of IVD reagent raw materials, deeply cultivating the research and development, production, and sales of core products such as blood vessel additives, biological buffering agents, chemiluminescence reagents, colorimetric reagents, enzyme preparations, etc. In the biological buffering agent sector, Xindesheng has formed a matrix of more than 50 products represented by Tris, HEPES, MOPS, Bicine, Caps, Taps, EPPS, PIPES, etc., with a stable purity of over 99%, and can customize indicators according to customer application scenarios. The company's daily production can reach 5 tons, with an annual output of 2000 tons, which can meet the full cycle raw material needs of IVD enterprises from research and development to mass production. In terms of product quality, Xindesheng strictly organizes production according to the ISO 9001 quality management system, with batch differences controlled within 1%. The products are widely used in high-end application scenarios such as in vitro diagnostic kits, cell culture media, and biopharmaceuticals. In addition to biological buffering agents, Xindesheng has also developed a series of chemiluminescence reagents represented by acridine ester and luminol, a series of chromogenic substrates represented by TOOS and MAOS, and a blood sample pretreatment product system represented by heparin lithium, heparin sodium, EDTA dipotassium, tripotassium, and serum separation gel, providing one-stop services from raw materials to solutions for IVD enterprises. With the continuous expansion of the Chinese biological buffer market and the deepening of the domestic substitution process for IVD core raw materials, Xindesheng will continue to leverage its technological advantages in chemical synthesis and large-scale production, continuously optimize product quality, enrich product pipelines, and provide high-purity, high batch consistency, and cost-effective core raw material guarantees for domestic and foreign IVD and biopharmaceutical enterprises. Recent developments of the company can be followed: the orderly promotion of the construction of Huanggang new production base, and the gradual realization of stable mass production of enzyme products such as amylase substrates. Welcome new and old customers and partners to call or write to discuss cooperation.

Starting from April 28, 2026, the inter provincial alliance led by Jiangxi Province to purchase sugar metabolism and other biochemical testing reagents in bulk will be officially implemented in multiple regions. This centralized procurement covers 35 commonly used clinical biochemical testing items, including glucose metabolism, liver function, kidney function, myocardial enzymes, pancreas, etc. The selected products have an average reduction of 70%, and some products have a reduction of over 98%. Biochemical diagnosis, a core sub field of in vitro diagnostics, has been fully included in the scope of centralized procurement. As a core supplier in the field of in vitro diagnostic (IVD) reagent raw materials, Hubei Xindesheng believes that the comprehensive implementation of centralized procurement is reshaping the competitive landscape of the industry, and high-quality, cost-effective, and highly stable diagnostic raw materials will play a key role in the new market environment. 1．Core data of centralized procurement: 154 companies selected, deep reshaping of price system According to the selection results released by the Jiangxi Provincial Medical Insurance Bureau, a total of 2314 specifications of biochemical testing reagents for sugar metabolism and other biochemical testing were selected from 154 enterprises through the inter provincial alliance procurement, with a proposed selection rate of 85%. The 35 types of testing items covered by the centralized procurement precisely focus on the diagnosis and treatment testing needs of chronic diseases such as diabetes, liver and kidney diseases, cardiovascular diseases, etc. In terms of price, this centralized procurement is unprecedented. The selected products have an average reduction of 70%, with some products experiencing a reduction of over 98%. 42 companies have quoted prices below 0.1 yuan per person for ion trace elements and sugar metabolism products. Among them, Roche Diagnostics, Beckman Coulter, Siemens Healthineers, Mindray Medical, and New Industries' "Calcium (CA)" products were all selected at a price of 0.07 yuan per person, New Industries' "Glucose (GLU)" was also selected at 0.07 yuan, and Roche Diagnostics' "Phosphorus (P)" was selected at 0.06 yuan. Some companies even quoted the lowest price of 0.03 yuan for the entire event. The procurement cycle for centralized procurement is 2 years, with the first year's procurement cycle from March 1, 2025 to February 28, 2026. As of now, public medical institutions in Ma'anshan, Tongling and other places in Anhui have fully launched the procurement and use of selected products. Relying on the price linkage mechanism of 26 provinces, the long-standing regional price differences have been effectively eliminated. 2．Industry impact: Cost pressure drives upstream raw material upgrades The comprehensive implementation of centralized procurement has had a profound impact on the IVD industry. Cost control capability has become the core competitiveness of downstream reagent production enterprises and medical institutions. According to industry analysis, centralized procurement has led to a change in the market size of approximately 7 billion yuan in the biochemical field. The categories covered by the three rounds of centralized procurement have accounted for about 90% of the biochemical IVD market. Under fierce price competition, 5 IVD companies and over 1400 product specifications have voluntarily withdrawn from the centralized procurement of liver function, kidney function, myocardial enzymes, and glucose metabolism biochemical reagents. Industry insiders point out that once the decline in the field of biochemical IVD exceeds 60%, manufacturers' profits will be severely impacted. In this context, the quality and cost efficiency of upstream raw materials have become key factors determining whether downstream reagent manufacturers can maintain positive cash flow after winning bids at low prices. As industry reports point out, centralized procurement forces midstream manufacturers to extend upstream and achieve self-developed and self-produced core raw materials or select cost-effective suppliers. The procurement cost and quality control of core raw materials have become key factors affecting competitiveness. The normalization of centralized procurement has made the prices of mid to low end biochemical reagents transparent, and enterprises that lack the ability to produce raw materials themselves or cannot effectively control raw material costs face direct clearance pressure. Hubei Xindesheng Material Technology Co., Ltd. has long focused on the field of IVD reagent raw materials, deeply cultivating the research and development, production, and sales of core products such as biological buffering agents, enzyme preparations, chromogenic substrates (chromogenic substrates), and blood collection tube additives. The company was formerly known as Wuhan Desheng Biochemical, established in 2005. After years of technological accumulation and continuous innovation, it has grown into a core enterprise in the field of IVD reagent raw materials in China. The company has completed the closed-loop process of two core products, EPS G7 amylase substrate and DGGR lipase substrate, and successfully connected the entire process from laboratory small-scale testing to kilogram scale mass production. The comprehensive implementation of inter provincial alliance centralized procurement of biochemical detection reagents such as sugar metabolism marks a new stage of "improving quality and controlling costs" in the biochemical diagnosis industry. For the IVD reagent raw material industry, the importance of quality stability, cost efficiency, and supply guarantee capability will be further highlighted. Hubei Xindesheng Material Technology Co., Ltd. will adhere to craftsmanship and quality, continuously increase research and development investment, empower the development of IVD in vitro diagnostic industry with more stable products, more professional technical support, and more competitive cost-effectiveness, and help the industry achieve high-quality development under the background of normalized centralized procurement.